INT241506

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.54
First Reported 2007
Last Reported 2008
Negated 0
Speculated 0
Reported most in Abstract
Documents 2
Total Number 2
Disease Relevance 2.37
Pain Relevance 0.04

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (Abl1) DNA binding (Abl1) cytoplasm (Abl1)
cytosol (Abl1) nucleolus (Abl1) cell adhesion (Abl1)
Anatomy Link Frequency
mast cell 1
Abl1 (Mus musculus)
Pain Link Frequency Relevance Heat
Bioavailability 3 74.40 Quite High
cva 4 5.00 Very Low Very Low Very Low
aspirin 4 5.00 Very Low Very Low Very Low
Pain 4 5.00 Very Low Very Low Very Low
Paracetamol 4 5.00 Very Low Very Low Very Low
corticosteroid 3 5.00 Very Low Very Low Very Low
palliative 3 5.00 Very Low Very Low Very Low
fibrosis 3 5.00 Very Low Very Low Very Low
Antihistamine 2 5.00 Very Low Very Low Very Low
Potency 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Myeloid Leukemia 106 98.98 Very High Very High Very High
Leukemia 20 98.88 Very High Very High Very High
Systemic Mastocytosis 12 98.18 Very High Very High Very High
Chronic Myelomonocytic Leukemia 15 97.40 Very High Very High Very High
Myelofibrosis 29 96.60 Very High Very High Very High
Hypereosinophilic Syndrome 14 96.02 Very High Very High Very High
Myelodysplastic Syndromes 61 95.28 Very High Very High Very High
Myeloproliferative Disorder 33 93.90 High High
Disease 30 53.40 Quite High
Chronic Myeloid Leukemia 1 30.32 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Recently, a potential role for autocrine GM-CSF secretion as a counterregulatory mechanism of Bcr-Abl positive cells to resist imatinib and nilotinib has been reported (Wang et al 2007).


Localization (secretion) of Abl
1) Confidence 0.54 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2503652 Disease Relevance 0.11 Pain Relevance 0.04
The MPDs (which include polycythemia vera (PV), essential thrombocythemia (ET), chronic eosinophilic leukemia (CEL), primary myelofibrosis (PMF), chronic myelomonocytic leukemia (CMML), and systemic mast cell disease (SMCD)) exclude chronic myeloid leukemia (CML) because of the pathognomic importance of the BCR-ABL translocation for the diagnosis and treatment of this disorder with imatinib mesylate.
Localization (translocation) of ABL in mast cell associated with leukemia, myeloid leukemia, myelofibrosis, myeloproliferative disorder, chronic myelomonocytic leukemia, hypereosinophilic syndrome, systemic mastocytosis and myelodysplastic syndromes
2) Confidence 0.37 Published 2007 Journal Biologics : Targets & Therapy Section Abstract Doc Link PMC2721304 Disease Relevance 2.25 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox